Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network

Open Access. Powered by Scholars. Published by Universities.®

Public Health

University of South Florida

Cancer prevention

Publication Year

Articles 1 - 2 of 2

Full-Text Articles in Entire DC Network

Defining Codes Based On The Consolidated Framework For Implementation Research In The Context Of The Implementing Universal Lynch Syndrome Screening, Jasmine A. Burton-Akright Mar 2021

Defining Codes Based On The Consolidated Framework For Implementation Research In The Context Of The Implementing Universal Lynch Syndrome Screening, Jasmine A. Burton-Akright

USF Tampa Graduate Theses and Dissertations

Lynch syndrome (LS) is the most common hereditary cause of both colorectal cancer (CRC) and endometrial cancer (EC). Universal tumor screening (UTS) of newly diagnosed EC and CRC patients has been shown to be both an effective and economical approach to identify patients with LS and subsequently reduce future cancer s for patients and their family members. Despite its efficacy, LS UTS has not been consistently adopted across hospital systems and existing programs vary widely in their structure and execution. The Implementing Universal Lynch Syndrome Screening (IMPULSS) study aims to determine the critical factors necessary for successful implementation of LS …


Understanding The Adoption Process Of An Hpv Vaccine School-Entry Requirement In Puerto Rico, Coralia Vázquez-Otero Apr 2019

Understanding The Adoption Process Of An Hpv Vaccine School-Entry Requirement In Puerto Rico, Coralia Vázquez-Otero

USF Tampa Graduate Theses and Dissertations

Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the US. Infection with low-risk HPV (i.e., 6 and 11) can cause genital warts, and persistent infection with high-risk HPV types (i.e., HPV 16 and 18) can progress to cancer. Currently, there is an HPV vaccine that is recommended for boys and girls, aged 11 to 12. Healthy People 2020 established a national objective of 80% completion of HPV vaccination among children aged 13 to 15 years old. Although the HPV vaccine is proven to be a safe and effective primary prevention strategy, uptake and completion rates remain …